Nuveen Asset Management LLC purchased a new stake in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 25,021 shares of the company's stock, valued at approximately $385,000. Nuveen Asset Management LLC owned approximately 0.17% of Inhibrx at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in INBX. PNC Financial Services Group Inc. purchased a new position in shares of Inhibrx in the 4th quarter worth approximately $28,000. Natixis purchased a new position in shares of Inhibrx in the 4th quarter worth approximately $31,000. JPMorgan Chase & Co. boosted its holdings in shares of Inhibrx by 47.8% in the 4th quarter. JPMorgan Chase & Co. now owns 7,592 shares of the company's stock worth $117,000 after purchasing an additional 2,457 shares during the period. New York State Common Retirement Fund purchased a new position in shares of Inhibrx in the 4th quarter worth approximately $53,000. Finally, Corebridge Financial Inc. purchased a new position in shares of Inhibrx in the 4th quarter worth approximately $89,000. Hedge funds and other institutional investors own 82.46% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, JMP Securities reissued a "market perform" rating on shares of Inhibrx in a research note on Thursday, May 15th.
Get Our Latest Analysis on INBX
Inhibrx Trading Up 8.0%
Shares of INBX traded up $1.03 during trading hours on Friday, hitting $13.92. The company had a trading volume of 91,386 shares, compared to its average volume of 109,863. The company has a market capitalization of $201.51 million and a PE ratio of 0.12. Inhibrx, Inc. has a one year low of $10.80 and a one year high of $17.79. The company's fifty day moving average price is $12.31 and its two-hundred day moving average price is $13.42.
Inhibrx (NASDAQ:INBX - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($2.80) earnings per share for the quarter, missing the consensus estimate of ($2.55) by ($0.25). Analysts forecast that Inhibrx, Inc. will post 104.88 earnings per share for the current year.
About Inhibrx
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
See Also
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
